Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Bill Wexler who wrote (4935)	7/16/1998 6:37:00 PM
From: Linda Kaplan	Read Replies (1) \| Respond to of 7041

Very cogent presentation. Thanks for going to the trouble to work it up. Linda

To: Bill Wexler who wrote (4935)	7/16/1998 6:57:00 PM
From: Peter V	Read Replies (1) \| Respond to of 7041

<<1) Vasomax does not help ED in any way (this is from Zonagen's own clinical trial results at the last AUA presentation and can be easily verified.)>>> A very slight exaggeration, Bill. When I was following this more closely a few months back, I recall that Vasomax did have a 12 percent efficacy rate over a placebo, but still only about 50 percent efficacy overall. If I were a physician, I'd be wary of prescribing a drug that only works in half the patients and only slightly better than a placebo, when Viagra has a much greater efficacy, and has been on the market for a fair amount of time, and has less side effects. The efficacy rate continues to be the death knell for Vasomax. It just doesn't appear to work very well, so why would the FDA approve it, and if they do, why would doctors prescribe it in any significant numbers?